Literature DB >> 15003941

HIFs and tumors--causes and consequences.

Gisele Höpfl1, Omolara Ogunshola, Max Gassmann.   

Abstract

For most organisms oxygen is essential fo life. When oxygen levels drop below those required to maintain the minimum physiological oxygen requirement of an organism or tissue it is termed hypoxia. To counter act possible deleterious effects of such a state, an immediate molecular response is initiated causing adaptation responses aimed at cell survival. This response is mediated by the hypoxia-inducible factor-1 (HIF-1), which is a heterodimer consisting of an alpha- and a beta-subunit. HIF-1 alpha protein is stabilized under hypoxic conditions and therefore confers selectivity to this response. Hypoxia is characteristic of tumors, mainly because of impaired blood supply resulting from abnormal growth. Over the past few years enormous progress has been made in the attempt to understand how the activation of the physiological response to hypoxia influences neoplastic growth. In this review some aspects of HIF-1 pathway activation in tumors and the consequences for pathophysiology and treatment of neoplasia are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003941     DOI: 10.1152/ajpregu.00538.2003

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  41 in total

1.  Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1alpha and the von Hippel-Lindau protein.

Authors:  Nobuyoshi Tajima; Kristina Schönherr; Susanna Niedling; Martin Kaatz; Hiroshi Kanno; Roland Schönherr; Stefan H Heinemann
Journal:  J Physiol       Date:  2006-01-05       Impact factor: 5.182

2.  Stress and adrenergic function: HIF1α, a potential regulatory switch.

Authors:  Dona Lee Wong; T C Tai; David C Wong-Faull; Robert Claycomb; Brenda J Siddall; Rose Ann Bell; Richard Kvetnansky
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

Review 3.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

4.  Pericellular oxygen depletion during ordinary tissue culturing, measured with oxygen microsensors.

Authors:  Erik O Pettersen; Lars Hauer Larsen; Niels Birger Ramsing; Peter Ebbesen
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

5.  Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha.

Authors:  Thomas Arnesen; Xianguo Kong; Rune Evjenth; Darina Gromyko; Jan Erik Varhaug; Zhao Lin; Nianli Sang; Jaime Caro; Johan R Lillehaug
Journal:  FEBS Lett       Date:  2005-11-02       Impact factor: 4.124

6.  Targeted therapy in ovarian cancer.

Authors:  Lyndsay J Willmott; John P Fruehauf
Journal:  J Oncol       Date:  2010-01-14       Impact factor: 4.375

7.  Comparative study of antioxidants as cancer preventives through inhibition of HIF-1 alpha activity.

Authors:  Jyoti Upadhyay; Rajesh K Kesharwani; Krishna Misra
Journal:  Bioinformation       Date:  2009-12-06

Review 8.  Erythropoietin but not VEGF has a protective effect on auditory hair cells in the inner ear.

Authors:  Arianne Monge Naldi; Max Gassmann; Daniel Bodmer
Journal:  Cell Mol Life Sci       Date:  2009-09-10       Impact factor: 9.261

9.  Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).

Authors:  Miho Iida; Kouji Banno; Megumi Yanokura; Kanako Nakamura; Masataka Adachi; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Takashi Iwata; Kyoko Tanaka; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-06-23

Review 10.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.